Yoshitaka Tamura

Purpose: To investigate whether virtual-monoenergetic images (VMI) from dual-layer spectral-detector computed tomography (DLCT) improve right adrenal vein (RAV) assessment before adrenal venous sampling (AVS), and portal-venous-phase (PVP) images alone can replace conventional multiphase CT combining late-arterial phase (LAP) and PVP. Methods: Sixty-three patients with primary aldosteronism who underwent LAP and PVP DLCT before AVS were retrospectively analyzed. Conventional polyenergetic-images (PEI) and VMI at 40–70 keV (VMI _40–70 ) were reconstructed. Image noise and contrast-to-noise ratio (CNR) of RAV were quantified. VMI with the highest CNR was predefined as the best-VMI. Two radiologists evaluated four image series (PEI and best-VMI at LAP and PVP) separately for RAV visibility, accessory hepatic vein (AHV) assessability, and image noise using five-point scales (1 = worst, 5 = best). RAV detection and AHV assessability rates were compared among image series. Results: In both enhancement phases, VMI _40–70 showed lower image noise and VMI _40–60 higher CNR than PEI (all p < 0.05), with VMI ₄₀ providing the highest CNR and being designated as the best VMI. Compared to PEI at LAP, CNR was lower with PEI at PVP but higher with VMI ₄₀ at PVP (both, p < 0.001). In subjective analysis, VMI ₄₀ showed better scores than PEI for image noise (LAP: 4.0 ± 0.5 vs. 2.4 ± 0.6; PVP: 4.0 ± 0.6 vs. 2.5 ± 0.5) and RAV visibility (LAP: 4.5 ± 0.8 vs. 3.5 ± 0.8; PVP: 3.7 ± 1.0 vs. 2.6 ± 0.9) (all p < 0.001). With PEI, the RAV detection rate was lower at PVP than at LAP (54.8% vs. 89.7%, p < 0.001). Use of VMI ₄₀ at PVP achieved the same detection rate as PEI at LAP (89.7%, p = 1.0) and higher AHV assessability rate than PEI at PVP (96.8% vs. 80.2%, p < 0.001). Conclusion: DLCT-VMI improved RAV assessments before AVS. Using VMI ₄₀ for PVP provided RAV depiction equivalent to PEI at LAP and superior AHV assessability to PEI at PVP, suggesting its potential as a surrogate for dedicated multiphase CT.

Purpose This study aimed to assess the safety and efficacy of endovascular treatment of unruptured pancreatic arcade aneurysms in a single-center series. Materials and Methods The electronic medical records of patients who underwent endovascular treatment for unruptured pancreatic arcade aneurysms between 2011 and 2022 at our tertiary center were retrospectively reviewed. The presence of celiac artery stenosis/occlusion; aneurysm number, location, and size; endovascular technique; procedure-related complication incidence; and clinical outcomes were assessed. Results Twenty-three patients (12 men and 11 women; mean [range] age, 63.8 [45–84] years) with 33 unruptured pancreatic arcade aneurysms were identified. Celiac artery stenosis/occlusion coexisted in 17 (74%) patients. Five (21%) patients had multiple aneurysms. The median aneurysm size was 9.3 mm (range, 4–18 mm). Seven, 6, 6, 5, 4, 3, and 2 aneurysms were located in the gastroduodenal, dorsal pancreatic, anterior superior pancreaticoduodenal, inferior pancreaticoduodenal, posterior inferior pancreaticoduodenal, posterior superior pancreaticoduodenal, and anterior inferior pancreaticoduodenal arteries, respectively. Four (15%) and 22 (85%) aneurysms were treated with endosaccular packing alone and coil embolization with endosaccular packing and parent artery occlusion, respectively, with resulting exclusion from arterial circulation. The remaining 7 aneurysms coexisting with larger aneurysms in other peripancreatic arteries were observed without embolization because they were small and for preserving collateral blood flow to the celiac artery. The treated aneurysms did not rupture or recur during the follow-up period (median, 40 months). Conclusion Endovascular treatment is a safe and effective treatment for unruptured pancreatic arcade aneurysms. Level of Evidence: 3, non-controlled retrospective cohort study. Graphical Abstract